Pharmacogenomics and Warfarin Management
While DOACs are the standard, thousands of Italian patients remain on Warfarin due to mechanical heart valves or specific kidney conditions. In 2026, these patients benefit from Pharmacogenomic Testing at the start of therapy.
By testing for specific genetic variants, Italian clinicians can predict exactly how a patient will metabolize Warfarin. This eliminates the "trial and error" phase of dosing, reaching the stable therapeutic range (INR) up to $50\%$ faster than traditional methods and significantly lowering the risk of complications during the first month of treatment.
2 Views